Adrenocortical carcinoma (ACC) is a rare endocrine malignancy, often with an unfavorable
prognosis. Here we summarize the knowledge about diagnosis, epidemiology …

Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-
lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab …

Adrenocortical carcinomas (ACCs) are aggressive cancers originating in the cortex of the
adrenal gland. Despite overall poor prognosis, ACC outcome is heterogeneous,. We …

Background Laparoscopic adrenalectomy (LA) is the standard treatment for benign adrenal
lesions. The laparoscopic approach has also been increasingly accepted for adrenal …

Adrenocortical carcinoma (ACC) is a devastating tumor for either patients or their families
because of short life expectancy and severe impact on quality of life. Due to the rarity of …

Context: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis in
need of more effective treatment options. Published evidence indicates many ACCs express …

Adrenocortical carcinoma (ACC) is an aggressive malignancy, which lacks an effective
systemic treatment. Abnormal activation of insulin-like growth factor receptor 1 (IGF1R) has …

Mitotane, 1, 1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (o, p'-DDD) is the most
effective medical therapy for adrenocortical carcinoma but its molecular mechanism of action …

Aims Adrenocortical carcinoma (ACC) carries a poor prognosis and current systemic
cytotoxic therapies result in only modest improvement in overall survival. In this retrospective …

Adrenocortical cancer is a rare malignancy. While surgery is the cornerstone of the
management of localized disease, metastatic disease is hard to treat. Cytotoxic …